UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
March 25, 2009
Date of Report (Date of earliest event reported)
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 000-29089 | 06-1562417 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
3 Forbes Road Lexington, MA |
02421 | |
(Address of principal executive offices) | (Zip Code) |
781-674-4400
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
On March 25, 2009, Antigenics Inc. (the Company) received notification from The NASDAQ Stock Market that the NASDAQ Listing Qualifications Panel (the Panel) had determined to transfer the Companys listing to The NASDAQ Capital Market and continue the Companys listing on that market effective with the opening of trading on March 27, 2009. The Companys shares will continue to trade under the ticker AGEN.
The Panels decision is subject to the condition that, among other things, the Company demonstrates compliance with all continued listing standards of The NASDAQ Capital Market on or before June 22, 2009. The Panels determination follows a hearing on January 29, 2009 at which the Panel considered the Companys plan to regain compliance with the minimum $35 million market value of listed securities or the alternative $2.5 million stockholders equity requirement for continued listing. While the Company is taking steps to comply with the terms of the Panel decision, there can be no assurance that the Company will be able to do so.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANTIGENICS INC. | ||||
Date: March 30, 2009 | By: | /s/ Garo H. Armen | ||
Garo H. Armen | ||||
Chief Executive Officer |